Model |
Assay System |
Disease |
Minimum Quantity of compound required |
Scientist involved |
ACE activity (kit based)
IC50 determination |
In vitro, Primary screening model |
CVS/hypertension |
10 mg |
Dr Kashif Hanif |
Spontaneously hypertensive rats Continuous BP and HR recording by Telemetry in conscious SHR/SD rat |
In vivo, Secondary screening animal model |
CVS/ hypertension |
500 mg |
Dr Rakesh Shukla |
Spontaneously hypertensive rats – For BP monitoring by non invasive blood pressure monitoring |
In vivo, Secondary screening animal model |
CVS/ hypertension |
150 mg
(Single dose) |
Dr Kashif Hanif |
Monocrotaline induced pulmonary hypertension |
In vivo, Primary screening animal model |
CVS/ Pulmonary hypertension |
1 gm/rat
(Single dose/day for 35 days) |
Dr Kashif Hanif |
Collagen induced platelet aggregation
IC50 determination |
In vitro assay |
CVS/Anti-platelet activity |
10 mg |
Dr Madhu Dikshit |
ADP induced platelet aggregation
IC50 determination |
In vitro assay |
CVS/Anti-platelet activity |
10 mg |
Dr Madhu Dikshit |
Arachidonic acid induced platelet aggregation
IC50 determination |
In vitro assay |
CVS/Anti-platelet activity |
10 mg |
Dr Madhu Dikshit |
Thromboxane A2 agonist (U46619) induced platelet aggregation
IC50 determination |
In vitro assay |
CVS/Anti-platelet activity |
10 mg |
Dr Madhu Dikshit |
Thrombin time
IC50 determination |
In vitro assay |
CVS/Anti-coagulant activity |
10 mg |
Dr Madhu Dikshit |
Prothrombin time
IC50 determination |
In vitro assay |
CVS/Anti-coagulant activity |
10 mg |
Dr Madhu Dikshit |
Activated partial thromboplastin time
IC50 determination |
In vitro assay |
CVS/Anti-coagulant activity |
10 mg |
Dr Madhu Dikshit |
Vasoreactivity EC50 determination |
In vitro Acetylcholine induced Vasorelaxation/ Phenylephrine induced vasoconstriction activity |
CVS/Vasorelaxant/ vasoconstriction activity |
15 mg |
Dr Madhu Dikshit / Dr Manoj K Barthwal |
Collagen-adrenaline induced thrombosis
Single dose |
In vivo
Primary Screening – Mice Model |
CVS/Anti-thrombotic |
5-10 mg |
Dr Madhu Dikshit |
Bleeding Time
Single dose |
In vivo
mice Model |
CVS/Anti-thrombotic |
5-10 mg |
Dr Madhu Dikshit |
FeCl3 induced Thrombosis
Single dose |
In vivo
Secondary Screening - Mice Model |
CVS/Anti-thrombotic |
5-10 mg |
Dr Madhu Dikshit |
FeCl3 induced Thrombosis
Single dose |
In vivo
Secondary Screening – Rat Model |
CVS/Anti-thrombotic |
200 mg |
Dr Madhu Dikshit |
Arterio-Venous Shunt Thrombosis
Single dose
|
In vivo
Secondary Screening - Rat Model |
CVS/Anti-thrombotic |
200 mg |
Dr Madhu Dikshit |
Anti-ischemic potential in myocardial infarction model in rats
Single dose |
Animal model |
CVS/ anti-ischemic |
250 mg |
Dr Madhu Dikshit |
Atherothrombosis in dyslipidemic hamsters (3 months fed on HFD)
Parameters to be investigated –
- FeCl3 induced thrombosis
- Plasma lipids
- Expression of inflammatory cytokines
- Coagulation cascade parameters: TT, PT, aPTT
- Platelet adhesion
- Platelet aggregation
- Vasoreactivity
|
In vivo Animal model |
CVS/
Atherosclerosis & intravascular thrombosis |
2 gm |
Dr Manoj K Barthwal |
Hyperlipidemic guinea model
- LDL Cholestrol
- HDL Cholestrol
- Triglycerides
- Total Cholestrol
|
In vivo
Animal model |
CVS/anti-dyslipidemic |
2 gm
(Single dose/day for 15 days) |
Dr Manoj K Barthwal |
Dexamethosone induced insulin resistance model in 3T3 L1 adipocyte- |
In vitro cell based assay |
CVS/anti-dyslipidemic |
10 mg |
Dr. Anil Gaikwad |
Chronic insulin model in 3T3 L1 adipocyte |
In vitro cell based assay |
CVS/anti-dyslipidemic |
10 mg |
Dr. Anil Gaikwad |
TNF induced insulin resistance model in 3T3 L1 adipocyte |
In vitro cell based assay |
CVS/anti-dyslipidemic |
10 mg |
Dr. Anil Gaikwad |
Inhibition of adipogenesis |
In vitro cell based assay |
CVS/Anti-dyslipidemic |
10 mg |
Dr. Anil Gaikwad |
Endothelial cell assays
- Tubulogenesis Assay
- Aortic ring assay
- 3D fibrin assay
|
In vitro cell based assays |
CVS/ Ischemia |
1-2 mg |
Dr. Kumaravelu Jagavelu |
Endothelial cell assays
- In vivo matrigel angiogenesis assay
- Ear Angiogenesis in mice
|
Animals models |
CVS/ Ischemia |
100 mg
(Single dose) |
Dr. Kumaravelu Jagavelu |
In vitro screening for Neuroprotective activity (PD) |
In vitro cell based assay |
CNS/ Neuroprotective |
1-5 mg |
Dr. Sarika Singh |
Screening for selective novel ligands for GPCRs implicated in CNS diseases.
Following receptor families will be used for screening (under development)
- Serotonin family: 5-HT1A, 5-HT4, 5-HT6, 5-HT7A/
- Dopamine family: D1-D4
- Histamine Receptor: H2, H4
- Opioid receptors: KOR DOR, MOR,
cAMP will be measureed in cells by GloSensor technology (for Gi- and Gs-coupled GPCRs)
|
In vitro
cell based assay |
CNS/ GPCRs |
2 mg for pure compounds and 10 mg for extracts |
Dr. Prem N. Yadav |
Screening of test compounds /extracts for their effect on, psychosis and cognition; Compounds with Ki values ≤ 10 nM in in vitro assays will be evaluated for
- Measurement of Pre-pulse inhibition (a test of sensory motor gating function) and Passive avoidance
|
In vivo animal model |
CNS/ memory/
psychosis |
50-100 mg for in vivo testing |
Dr. P.N. Yadav |
Animal models for learning and memory
- Passive Avoidance test/Morris Water Maze test
- Inhibition of Acetylcholinesterase activity
|
In vivo animal model
In vitro |
CNS/Learning and memory |
250 mg
50 mg |
Dr C Nath/ Dr Rakesh Shukla |
Parkinson’s models
- MPTP and Rotenone induced rodent model of Parkinson’s disease (PD)
- Assessment of behavioural deficits by neurobehavioral tests
- Open field activity
- Rotarod
- Assessment of biochemical deficits by estimating levels of neurotransmitters and IHC
|
In vivo
Animal models of PD |
Neurodegeneration |
100-200 mg |
Dr Shubha Shukla |
Anti Psychotic activity
- Gross behavior: Locomotor activity, Anti anxiety: Elevated Plus maze
- Anti-depressant: Tail suspension and forced swim test
- NMDA receptor modulated animal model of Schizophrenia
|
In vivo
Behavioural animal models |
CNS/ Anti-anxiety |
100 mg |
Dr PN Yadav |
C. elegans models for neurodegenerative diseases
- Activity against beta amyloid aggregation in C. elegans.
- Activity against alpha synuclein aggregation in C. elegans.
|
In vivo
Transgenic C. elegans based assays
In vivo
Transgenic C. elegans based assays
|
CNS/ Alzheimer’s
CNS/ Parkinson’s
|
5 mg
20 mg
5 mg
20 mg
|
Dr Amir Nazir |
Anti-inflammatory activity
- COX-1/COX2 (kit based)
- TNFα Inhibition (kit based)
|
In vitro
cell based assay |
Other disorder/
Anti-inflammatory |
10 mg |
Dr Rakesh Shukla |
Anti-inflammatory activity
- Carrageenan induced paw edema in rat/mice
|
In vivo
Animal models |
Other disorder/Anti-inflammatory |
250 mg |
Dr Rakesh Shukla |
Anti-ulcer activity
- Primary screening- Cold restrain induced ulcers
Secondary screening
- Aspirin induced ulcer (Ulcer index)
- Pyloric ligation model (free and total acidity)
|
In vivo
animal models |
Other disorder
/Anti-ulcer activity |
100 mg |
Dr Madhu Dikshit |
